Quick Summary
- GSK is purchasing Nuvalent in a $10.6 billion all-cash transaction priced at $124 per share
- The acquisition price represents a 40% premium above Monday’s market close
- Nuvalent shares surged 39% to reach $122.90 during Tuesday’s early market session
- GSK acquires three non-small cell lung cancer treatment programs, with two awaiting FDA approval decisions in late 2026
- This marks GSK’s biggest acquisition deal in more than ten years
British pharmaceutical giant GSK revealed Tuesday its plan to purchase Boston-headquartered oncology drugmaker Nuvalent in a $10.6 billion cash transaction, propelling Nuvalent shares upward by 39% to $122.90.
The $124-per-share purchase price delivers a 40% premium over Nuvalent’s Monday closing value. GSK’s American depositary receipts remained flat at $50.65, though GSK’s London-traded shares declined over 3%.
This transaction represents GSK’s most substantial acquisition in more than a decade, signaling a significant strategic realignment for the British pharmaceutical powerhouse.
The acquisition delivers GSK three non-small cell lung cancer development programs. The primary assets include zidesamtinib, designed to target ROS1 mutations, and neladalkib, functioning as an ALK inhibitor.
Both medications are in advanced-stage development and currently undergoing FDA evaluation. Regulatory determinations are anticipated on September 18 and November 27, 2026, respectively.
A third compound, NVL-330, represents a HER2 inhibitor presently in phase I clinical trials.
“These two primary products represent potentially best-in-class assets with possible launches this year pending FDA approval,” stated GSK CEO Luke Miels.
GSK’s Strategic Return to Cancer Treatment
GSK had previously traded its oncology division to Novartis in exchange for Novartis’ vaccines business in 2014. This acquisition signals a definitive reentry into cancer therapeutics as a strategic priority.
Miels, who assumed the CEO position in early 2026, had earlier communicated to shareholders a preference for acquisitions in the £2 billion to £4 billion spectrum. He justified the elevated price point by noting the deal essentially secures three separate products in one transaction.
After accounting for acquired cash, GSK’s net investment totals approximately $9.4 billion. The company plans to finance the deal through a combination of new and existing debt instruments plus available cash, with no anticipated effect on GSK’s credit standing.
Financial Implications for GSK
GSK confirmed its current 2026 full-year financial guidance remains unaffected. The pharmaceutical company anticipates the acquisition will begin contributing to revenue and core operating profit starting in 2027, with positive core earnings per share impact materializing in 2029.
GSK indicated the acquisition will help bolster core operating profit during the dolutegravir patent exclusivity loss period spanning 2028 through 2030.
The transaction is projected to expedite GSK’s entrance into the lung cancer market and establish a foundation for additional growth alongside Ris-Rez, its B7-H3 antibody-drug conjugate currently advancing through phase III trials.
Pending regulatory clearances, including Hart-Scott-Rodino Act approval, both organizations anticipate completing the transaction prior to the conclusion of Q3 2026.
FDA decisions regarding Nuvalent’s two primary drug candidates are slated for September 18 and November 27, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
